6.1.1.15 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27216312&form=6&db=m Validation of the Simbionix PROcedure Rehearsal Studio sizing module: A comparison of software for endovascular aneurysm repair sizing and planning. therapeutic application,unassigned 1,0 6.1.1.15 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27612429&form=6&db=m EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer. causal interaction,unassigned 3,0 6.1.1.15 Coccidiosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28867614&form=6&db=m Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. therapeutic application,unassigned 4,0 6.1.1.15 Coinfection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30521835&form=6&db=m A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses. therapeutic application,unassigned 1,0 6.1.1.15 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33791697&form=6&db=m The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 6.1.1.15 Cryptosporidiosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28867614&form=6&db=m Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. therapeutic application,unassigned 4,0 6.1.1.15 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30521835&form=6&db=m A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses. therapeutic application,unassigned 1,0 6.1.1.15 Diffuse Cerebral Sclerosis of Schilder http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25629079&form=6&db=m Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome. causal interaction,unassigned 1,0 6.1.1.15 Diffuse Cerebral Sclerosis of Schilder http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29915213&form=6&db=m The genotypic and phenotypic spectrum of PARS2-related infantile-onset encephalopathy. causal interaction,unassigned 1,0 6.1.1.15 Gastroenteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25759500&form=6&db=m Identification of a gamma interferon-activated inhibitor of translation-like RNA motif at the 3' end of the transmissible gastroenteritis coronavirus genome modulating innate immune response. unassigned - 6.1.1.15 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30524284&form=6&db=m Glutamyl-Prolyl-tRNA Synthetase Regulates Epithelial Expression of Mesenchymal Markers and Extracellular Matrix Proteins: Implications for Idiopathic Pulmonary Fibrosis. causal interaction,ongoing research,unassigned 3,2,0 6.1.1.15 Intestinal Volvulus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31046663&form=6&db=m Genomic analyses of aminoacyl tRNA synthetases from human-infecting helminths. therapeutic application,unassigned 4,0 6.1.1.15 Leishmaniasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28867614&form=6&db=m Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. therapeutic application,unassigned 4,0 6.1.1.15 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25047712&form=6&db=m Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase. therapeutic application,unassigned 1,0 6.1.1.15 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25569515&form=6&db=m Halofuginone - the multifaceted molecule. causal interaction,therapeutic application,unassigned 4,1,0 6.1.1.15 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25995223&form=6&db=m The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. causal interaction,therapeutic application,unassigned 1,2,0 6.1.1.15 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27798837&form=6&db=m Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. therapeutic application,unassigned 4,0 6.1.1.15 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28867614&form=6&db=m Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. therapeutic application,unassigned 4,0 6.1.1.15 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17018635&form=6&db=m The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. diagnostic usage,therapeutic application,unassigned 1,1,0 6.1.1.15 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27612429&form=6&db=m EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer. causal interaction,unassigned 3,0 6.1.1.15 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29596499&form=6&db=m Specific protein carbonylation in human breast cancer tissue compared to adjacent healthy epithelial tissue. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 6.1.1.15 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33740160&form=6&db=m EPRS/GluRS promotes gastric cancer development via WNT/GSK-3?/?-catenin signaling pathway. causal interaction,therapeutic application,unassigned 3,1,0 6.1.1.15 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29915213&form=6&db=m The genotypic and phenotypic spectrum of PARS2-related infantile-onset encephalopathy. causal interaction,unassigned 1,0 6.1.1.15 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24489094&form=6&db=m Halofuginone-induced amino acid starvation regulates Stat3-dependent Th17 effector function and reduces established autoimmune inflammation. causal interaction,unassigned 1,0 6.1.1.15 Starvation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25569515&form=6&db=m Halofuginone - the multifaceted molecule. causal interaction,therapeutic application,unassigned 4,1,0 6.1.1.15 Toxoplasmosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28867614&form=6&db=m Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis. therapeutic application,unassigned 4,0 6.1.1.15 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27595231&form=6&db=m Infection-specific phosphorylation of glutamyl-prolyl tRNA synthetase induces antiviral immunity. causal interaction,unassigned 1,0